Multi-parameter Diagnostic Blood Test for the Diagnosis of Alzheimer's Disease

Validation Trial for a Multi-parameter Diagnostic Blood Test for the Diagnosis of Alzheimer's Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02409030

Acronym

RH-VAL

Enrollment

700

Registered

2015-04-06

Start date

2014-01-31

Completion date

2017-10-18

Last updated

2019-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Brief summary

The purpose of this study is to validate a diagnostic test that combines different blood markers to identify and correctly classify patients with Alzheimer's disease (AD) compared to individuals with behavioural variant frontotemporal dementia (bvFTD, patient control) versus cognitively healthy individuals (healthy control).

Detailed description

The purpose of this study is to validate a new multi-parameter diagnostic test, on a well-characterised population based on new AD diagnostic criteria, that combines different types of markers, selected based on prior exploratory studies carried out by Raman Health Technologies.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

1. Healthy controls: * Aged between 50-80 years. * Men and women. * Assessment of the neuropsychological tests confirming the absence of cognitive impairment. * Prior to participant inclusion, obtaining the results of the CerebroSpinal Fluid marker analysis (beta-amyloid, Tau protein and p-Tau) carried out in the 24 months before recruitment. 2. Patients diagnosed with Alzheimer's disease (AD). * Aged between 50-80 years. * Men and women. * Patients meet the clinical criteria for Alzheimer's disease: * Prior to participant inclusion, results obtained from CerebroSpinal Fluid marker analysis (beta-amyloid, Tau protein and p-Tau) carried out in the 36 months before recruitment. 3. Patients with behavioural variant frontotemporal dementia and primary progressive aphasia: - * Aged between 50-80 years. * Men and women. * Patient meets the clinical criteria of behavioural variant frontotemporal dementia (bvFTD), or syndromes associated with temporal variants that affect language (primary progressive aphasia, agrammatic and semantic subgroups): (Mild Cognitive Impairment) sub-study: Patients with mild cognitive impairment will be included * Aged between 50-80 years. * Men and women. * Patient meets the clinical criteria for mild cognitive impairment: * Clinical diagnostic criteria for mild cognitive impairment: NIA-Alzheimer's Association of America criteria, Alzheimer's Dementia, 2011 * Prior to participant inclusion, results obtained from cerebrospinal fluid marker analysis (beta-amyloid, Tau protein and p-Tau) carried out in the 12 months before recruitment.

Exclusion criteria

* Severe or acute systemic disease that could impede the participant's follow-up study: Advanced liver or kidney disease and disseminated neoplastic disease * Addiction to alcohol or other drugs in the last two years based on Diagnostic and Statistical Manual of Mental Disorders IV criteria, except nicotine use, which is permitted * Down's syndrome * Moderate or severe head injury * central nervous system infections (HIV, syphilis, borrelia, herpes simplex, suspected Creutzfeldt-Jakob disease) * Endocrine alterations (thyroid alterations) * Nutritional deficiency (vitamin B12, folic acid) * Clinical history of stroke in the previous three months or neuroimaging evidence of clinically significant cardiovascular disease (e.g. strategic infarct or severe leukoencephalopathy). * Neurological diseases (dysmyelinating disorders, Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, subdural haematoma, brain tumours) * Major psychiatric disorder (major depression or psychosis) * Patients who do not have a clearly defined clinical diagnosis according to the study groups (inclusion/

Design outcomes

Primary

Measure	Time frame	Description
Blood markers	Up to 12 months	Multi-parameter determination: Raman laser and infrared spectroscopic markers, Metabolite-based markers (A02, A16, A22 ST01 F20 M30), Protein markers (A, A-T, B, PRO-B, C, C1, C2, PROGRANULIN), Biochemical markers (OXIDATIVE STRESS MARKERS, CTAN, ROUTINE BIOCHEMICAL MARKERS (GLUCOSE, TRIGLYCERIDES) and Genetic markers (ApoE, ApoC).

Countries

Belgium, France, Spain

Outcome results